Drugs · acquisition-cost intelligence
Quillivant XR
methylphenidate hydrochloride· ingredient methylphenidate· METHYLPHENIDATE HYDROCHLORIDE 300 mg/60mL; METHYLPHENIDATE HYDROCHLORIDE 600 mg/120mL; METHYLPHENIDATE HYDROCHLORIDE 750 mg/150mL; METHYLPHENIDATE HYDROCHLORIDE 900 mg/180mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$2.43
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other methylphenidate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Methylin | $0.11303 | −$2.32 |
| Ritalin | $0.16210 | −$2.27 |
| Methylphenidate Hydrochloride | $0.49387 | −$1.94 |
| Methylphenidate Hydrochloride | $0.66777 | −$1.76 |
| Methylphenidate Hydrochloride Extended-Release | $0.69976 | −$1.73 |
| CONCERTA | $0.69976 | −$1.73 |
| methylphenidate hydrochloride CD | $1.49 | −$0.93720 |
| Methylphenidate Hydrochloride | $1.91 | −$0.52190 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.